AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor omapatrilat and the angiotensin-converting enzyme inhibitor (ACEI) captopril in the postmyocardial infarction (MI) rat model.BackgroundThe cardioprotective effects of ACEIs after MI are thought to be partially due to an increase in bradykinin (BK). Vasopeptidase inhibitors inhibit both ACE and neutral endopeptidase (NEP), further reduce BK metabolism and increase natriuretic peptides, which may result in better cardioprotective effects than with ACEIs after MI.MethodsMyocardial infarction was induced in 514 Wistar male rats by ligation of the anterior coronary artery. Rats surviving 4 h after MI (n = 282) were assigned to omapatrilat (40 or 80...
Background: The aim of the present study was to evaluate the cardiovascular effects of the novel bra...
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase and angiotensin-converti...
We evaluated the effects of a new angiotensin-converting enzyme (ACE) inhibitor (idrapril) in terms ...
AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor o...
AbstractObjectives. This study sought to compare the effects of angiotension-converting enzyme inhib...
Angiotensin I converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure. ...
During the last 25 years angiotensin-converting enzyme inhibitors spectacularly conquered the field ...
Study objective - The aim was to compare the effects of two novel angiotensin converting enzyme (ACE...
In this study the effect of the angiotensin converting enzyme (ACE) inhibitor captopril on beta-rece...
Abstract: Background and objective: Angiotensin-converting enzyme (ACE) inhibitors have been reporte...
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce the incidence of future cor...
Objective – Angiotensin-converting enzyme inhibi-tors (ACEIs) have gained importance in preventing o...
Microvascular remodeling contributes to increased cardio-vascular risk in hypertension. The dual ang...
OBJECTIVES: The goal of this study was to compare the relative efficacy of an angiotensin-converting...
Purpose: To investigate the influence of angiotensin-converting enzyme inhibitor (ACEI) on cardiac i...
Background: The aim of the present study was to evaluate the cardiovascular effects of the novel bra...
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase and angiotensin-converti...
We evaluated the effects of a new angiotensin-converting enzyme (ACE) inhibitor (idrapril) in terms ...
AbstractObjectivesThe goal of this study was to compare the effects of the vasopeptidase inhibitor o...
AbstractObjectives. This study sought to compare the effects of angiotension-converting enzyme inhib...
Angiotensin I converting enzyme (ACE) inhibitors are widely used in the treatment of heart failure. ...
During the last 25 years angiotensin-converting enzyme inhibitors spectacularly conquered the field ...
Study objective - The aim was to compare the effects of two novel angiotensin converting enzyme (ACE...
In this study the effect of the angiotensin converting enzyme (ACE) inhibitor captopril on beta-rece...
Abstract: Background and objective: Angiotensin-converting enzyme (ACE) inhibitors have been reporte...
Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce the incidence of future cor...
Objective – Angiotensin-converting enzyme inhibi-tors (ACEIs) have gained importance in preventing o...
Microvascular remodeling contributes to increased cardio-vascular risk in hypertension. The dual ang...
OBJECTIVES: The goal of this study was to compare the relative efficacy of an angiotensin-converting...
Purpose: To investigate the influence of angiotensin-converting enzyme inhibitor (ACEI) on cardiac i...
Background: The aim of the present study was to evaluate the cardiovascular effects of the novel bra...
Omapatrilat, a vasopeptidase inhibitor, inhibits both neutral endopeptidase and angiotensin-converti...
We evaluated the effects of a new angiotensin-converting enzyme (ACE) inhibitor (idrapril) in terms ...